Bookings revived the Novanta thesis
- Novanta is a picks-and-parts supplier for medical device makers and advanced industrial OEMs.
- Q1 2026 bookings grew 37% year over year, with a book-to-bill of 1.10.
- Automation revenue rose 6.6% to $131.2M, and bookings in that segment jumped 50%.
- Medical Solutions revenue rose 14.8% to $126.5M, helped by Keonn and a return to 2% core organic growth.
- The main risk is margin timing: tariffs, freight, and materials hit before surcharges can catch up.
A sharp turn after a weak 2025
Novanta looked stuck in 2025. The Medical business had organic pressure, including a $12.6M year-over-year decline in precision medicine products for FY2025. Automation also failed to hold a clean recovery through the year.
Q1 2026 changed the picture. Total bookings grew 37% year over year, with a book-to-bill of 1.10. Automation bookings grew 50%, helped by robotics, semiconductor, and GenAI infrastructure demand. Medical returned to modest core organic growth of 2%.
The bull case is that Novanta has found two stronger lanes: GenAI infrastructure and robotic or minimally invasive surgery. Management said GenAI infrastructure was about 15% of first-quarter sales and growing more than 20% year over year. New work tied to EUV and DUV lithography, plus NVIDIA Halos AI Systems Inspection Lab recognition, could help turn prototypes into production orders.
The bear case is still about proof. Gross margin was pressured in Q1 2026 by tariffs, freight, and material costs. Management expects surcharges and factory changes to help in the second half of 2026, but investors need to see that happen. The stock also needs a better answer on price before the story can be treated as low risk.
Precision parts for long OEM programs
Novanta makes critical components and subsystems that other companies build into their own machines. Its customers are mainly OEMs, meaning original equipment manufacturers. These buyers care about precision, safety, reliability, and long product lives.
The model works best when Novanta wins a spot inside a customer platform that ships for years. A medical device or factory tool can take a long time to design and approve. Once Novanta is built in, switching suppliers can be costly and risky for the customer.
That strength can also become a weakness. If a customer delays a machine launch, cuts orders, or pushes back on price surcharges, Novanta feels it. The company is also exposed to cycles in industrial automation, semiconductor tools, and AI infrastructure spending.
What Novanta sells
Laser and photonics components
These include laser beam delivery parts, laser sources, and related optical systems. They are used in precision industrial and medical applications where accuracy matters.
Encoders, motors, and servo drives
These products help machines know where they are and move with high precision. Demand improved in Q1 2026 as robotics and automation orders recovered.
Air bearing spindles and semiconductor tooling parts
These are used in high-end manufacturing tasks such as GPU drilling, probe card production, and lithography-related work. The internal thesis expects a DUV and EUV ramp in the second half of 2026.
Robotic end-of-arm technology
These are the parts near the working end of a robot. NVIDIA Halos AI Systems Inspection Lab recognition gives Novanta a possible path into safety-validated AI-driven robotics.
Insufflators, pumps, and surgical systems
These medical products support minimally invasive surgery. Next-generation insufflators are one of the key drivers inside Medical Solutions.
Medical consumables and disposables
Consumables can bring repeat revenue after equipment is placed. The open question is the exact run-rate and margin profile compared with older capital equipment lines.
RFID and barcode technologies
Keonn added RFID technology to the Medical Solutions segment in 2025. The deal helped reported growth, but investors still need to track how much growth is organic.
Two segments, two cycles
The segment shares use Q1 2026 segment revenue: $131.2M from Automation Enabling Technologies and $126.5M from Medical Solutions. End-market mix can differ from segment mix because some technologies serve both medical and industrial customers.
What could break the rebound
Surcharges fail to catch costs
High impact · Medium oddsQ1 2026 gross margin was hurt by freight, tariffs, and material costs. Management expects price surcharges to catch up by the second half of 2026. If OEM customers resist those charges, the margin recovery could miss.
AI infrastructure orders are pulled forward
High impact · Medium oddsGenAI infrastructure was about 15% of Q1 sales and was growing more than 20% year over year. That is helpful, but it could reflect urgent early build-outs rather than a long cycle. If prototype work does not become production volume, the new bull case weakens.
Medical growth stays acquisition-led
Medium impact · Medium oddsMedical Solutions revenue grew 14.8% in Q1 2026, helped by Keonn. The better sign was 2% core organic growth, but that is still modest. If the segment slides back into organic decline, the company will look more dependent on deals.
Supply chain and energy shock
Medium impact · Medium oddsThe Q1 2026 filing called out the February 2026 escalation involving the United States, Israel, and Iran. Novanta does not have material Middle East operations, but the conflict raised supply chain risk, energy prices, freight costs, and commodity costs. Another shock could hit costs before pricing resets.
OEM program concentration
Medium impact · Low oddsNovanta often wins by being designed into long-lifecycle customer platforms. That creates sticky revenue, but it also ties growth to customer launch timing. A delayed surgery platform, semiconductor tool, or robotics program can push revenue out.
In one breath
What does Novanta actually do?
Novanta makes precision components and subsystems for medical and advanced industrial OEMs. Its products help machines see, move, measure, cut, drill, pump, and control with high accuracy.
Why did the Novanta thesis improve in 2026?
Q1 2026 bookings grew 37% year over year, and the book-to-bill was 1.10. Automation bookings jumped 50%, while Medical returned to modest core organic growth.
How is Novanta connected to AI?
Management said GenAI infrastructure was about 15% of first-quarter sales and growing more than 20% year over year. The exposure includes semiconductor manufacturing tools, GPU-related drilling, probe card production, and AI-driven robotics validation.
What is the biggest thing to watch next?
Watch whether gross margin improves in the second half of 2026. The company needs price surcharges and facility actions to offset tariffs, freight, and material cost pressure.